Formula I IRAK4 Inhibitor Composition for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory diseases and cancers related to interleukin-1 receptor-associated kinase (IRAK) are inadequate, particularly in managing conditions such as rheumatoid arthritis, tumors, and other IRAK4-mediated disorders.
Innovation Solution
Development of a novel compound of formula I, its stereoisomers, racemates, or pharmaceutically acceptable salts, which selectively inhibit IRAK4 activity, formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for inflammatory diseases and cancers related to IRAK, then current therapeutic options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent introduces a novel compound of formula I with specific chemical structure parameters that selectively inhibit IRAK4 activity. By changing the therapeutic agent from existing treatments to this new compound with optimized molecular structure (including specific heteroaryl/heterocyclyl groups, substituents R1-R6, and structural features), the patent achieves improved treatment effectiveness for IRAK-mediated diseases while maintaining therapeutic versatility
Solution Approach 2:
The compound of formula I acts as an intermediary substance that selectively binds to and inhibits IRAK4 kinase activity. This intermediary mechanism blocks the IRAK4-dependent TLR/IL-1R signaling pathway, thereby treating inflammatory diseases and cancers without affecting other biological systems, resolving the contradiction between effective treatment and targeted therapy
2Reliability
If IRAK4 activation is blocked to treat inflammatory diseases, then disease progression is controlled, but selectivity against other kinases must be maintained
Solution Approach 1:
The compound of formula I exhibits local quality through its selective inhibition of IRAK4 kinase specifically, while sparing other kinases. The molecular structure includes specific heteroaryl/heterocyclyl groups (ring A with N-containing 5-14 membered rings), substituents R1-R6, and structural features that create selective binding affinity for IRAK4's active site, ensuring disease control without off-target effects on other biological pathways
Solution Approach 2:
The patent employs asymmetry in the compound's molecular structure, where ring A is specifically defined as a 5-14 membered heteroaryl or 5-12 heterocyclyl containing at least one N, with asymmetric substitution patterns (R1, R2, R3 independently selected from specific groups). This asymmetric structural design enables selective interaction with IRAK4's asymmetric binding pocket, achieving high selectivity and preventing harmful off-target effects
Data Source
AI summary
Disclosed is a compound represented by formula I, a stereoisomer, racemate, tautomer, isotopic label, prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and medical use thereof. The structure is as shown in formula I.